The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2009-08-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0906606106PMID 19625624PMCID PMC2714280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

  2009cited by this paper
• A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

  2009cited by this paper
• EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma

  2009influential reference
• An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

  2009cited by this paper
• Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

  2008cited by this paper
• Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

  2008cited by this paper
• Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

  2008cited by this paper
• The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

  2008cited by this paper
• The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

  2008cited by this paper
• Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.

  2008cited by this paper
• S6K1 plays a key role in glial transformation.

  2008cited by this paper
• AMPK phosphorylation of raptor mediates a metabolic checkpoint.

  2008cited by this paper
• Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

  2008cited by this paper
• Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma

  2008cited by this paper
• PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

  2007cited by this paper
• Regulation of Endothelial Cell Cycle by Laminar Versus Oscillatory Flow: Distinct Modes of Interactions of AMP-Activated Protein Kinase and Akt Pathways

  2007cited by this paper
• AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling

  2007cited by this paper
• The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells.

  2007cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

  2007cited by this paper
• The Role of AMPK and mTOR in Nutrient Sensing in Pancreatic β-Cells*

  2007cited by this paper
• Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Lipidomics: a global approach to lipid analysis in biological systems Published, JLR Papers in Press, August 10, 2006.

  2006cited by this paper
• Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

  2006cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• A method of image registration for small animal, multi-modality imaging

  2006cited by this paper
• Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

  2006cited by this paper
• A thematic review series: systems biology approaches to metabolic and cardiovascular disorders

  2006cited by this paper
• Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver.

  2005cited by this paper
• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  2005cited by this paper
• Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype.

  2005cited by this paper
• The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

  2004cited by this paper
• AMIDE: a free software tool for multimodality medical image analysis.

  2003cited by this paper
• TSC2 mediates cellular energy response to control cell growth and survival.

  2003cited by this paper
• Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

  2003cited by this paper
• Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

  2001cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner.

  1998cited by this paper
• Characterisation of 5'-AMP-activated protein kinase in human liver using specific peptide substrates and the effects of 5'-AMP analogues on enzyme activity.

  1994cited by this paper
• Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism.

  1994cited by this paper
• On respiratory impairment in cancer cells.

  1956cited by this paper
• On respiratory impairment in cancer cells.

  1956cited by this paper
• [Origin of cancer cells].

  1956cited by this paper
• On the origin of cancer cells.

  1956cited by this paper

• Chemotherapy induces multiple sclerosis-like neuropathologies that can be rescued by clobetasol.

  2025cites this paper
• AMPK/SIRT1/PGC‐1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy

  2025cites this paper
• Inhibition of TRAF3IP2 Modulates NAMPT and NAD Metabolism in Glioblastoma

  2025cites this paper
• Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance

  2025cites this paper
• Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.

  2025cites this paper
• Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials

  2024cites this paper
• Eye on the horizon: The metabolic landscape of the RPE in aging and disease

  2024cites this paper
• Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

  2024cites this paper
• Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma.

  2024cites this paper
• The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research

  2024cites this paper
• One-carbon-mediated purine synthesis underlies temozolomide resistance in glioblastoma

  2024cites this paper
• Lipidomics-driven drug discovery and delivery strategies in glioblastoma.

  2024cites this paper
• Free fatty acids induce coronary microvascular dysfunction via inhibition of the AMPK/KLF2/eNOS signaling pathway

  2023cites this paper
• Millet Bran Protein Hydrolysate Displays the Anti-non-alcoholic Fatty Liver Disease Effect via Activating Peroxisome Proliferator-Activated Receptor γ to Restrain Fatty Acid Uptake.

  2023cites this paper
• Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics

  2023cites this paper
• Recent advances in understanding brain cancer metabolomics: a review

  2023cites this paper
• SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells

  2023cites this paper
• Anti-tumor activity of 5-aminoimidazole-4-carboxamide riboside with AMPK-independent cell death in human adult T-cell leukemia/lymphoma.

  2023cites this paper
• p53 promotes peroxisomal fatty acid β-oxidation to repress purine biosynthesis and mediate tumor suppression

  2023cites this paper
• Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer

  2023cites this paper
• The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment

  2023cites this paper
• An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1

  2023cites this paper
• Pathogenic role of 25-hydroxycholesterol in cancer development and progression.

  2023cites this paper
• Glioblastoma Metabolism: Insights and Therapeutic Strategies

  2023cites this paper
• Targeting fatty acid metabolism in glioblastoma

  2023cites this paper
• Key events in cancer: Dysregulation of SREBPs

  2023cites this paper
• A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening

  2022cites this paper
• Emerging role of ferroptosis in glioblastoma: Therapeutic opportunities and challenges

  2022cites this paper
• Inhibition of osteosarcoma cell proliferation in vitro and tumor growth in vivo in mice model by alstonine through AMPK-activation and PGC-1α/TFAM up-regulation.

  2022influential citation
• Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage

  2022cites this paper
• MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state

  2022influential citation
• Disorders of cancer metabolism: The therapeutic potential of cannabinoids.

  2022cites this paper
• Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights

  2022cites this paper
• Control of cell metabolism by the epidermal growth factor receptor.

  2022cites this paper
• Targeting Energy Metabolism to Overcome Therapeutic Resistance of Glioblastoma and Tumor-associated Edema

  2021cites this paper
• The Effects of Sterol-Related Signaling Pathways on Glioma

  2021cites this paper
• AMPK–mTOR Signaling and Cellular Adaptations in Hypoxia

  2021cites this paper
• Robust Prediction of Personalized In Vivo Response to Unseen Drugs From In Vitro Screens Using a Novel Context-Aware Deconfounding Autoencoder

  2021cites this paper
• Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

  2021cites this paper
• Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity.

  2021cites this paper
• AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review

  2021cites this paper
• Lipid Metabolism in Cancer Cells.

  2021cites this paper
• High Sub-Zero Organ Preservation: A Paradigm of Nature-Inspired Strategies.

  2021cites this paper
• Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

  2021cites this paper
• Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression

  2021cites this paper
• Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors

  2021cites this paper
• One-Carbon Metabolism Associated Vulnerabilities in Glioblastoma: A Review

  2021influential citation
• Metabolic Vulnerabilities in Brain Cancer.

  2021cites this paper
• Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets

  2020cites this paper
• Insulin and Metformin Control Cell Proliferation by Regulating TDG-Mediated DNA Demethylation in Liver and Breast Cancer Cells

  2020cites this paper
• Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma

  2020cites this paper
• DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy

  2020cites this paper
• Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies

  2020cites this paper
• Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.

  2020cites this paper
• AMPK: Potential Therapeutic Target for Alzheimer's disease.

  2020cites this paper
• Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway.

  2020cites this paper
• Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma

  2020cites this paper
• Nickel‐induced VEGF expression via regulation of Akt, ERK1/2, NFκB, and AMPK pathways in H460 cells

  2019cites this paper
• Yeast to Study Human Purine Metabolism Diseases

  2019cites this paper
• Metabolic reprogramming in the pathogenesis of glioma: Update

  2019cites this paper
• Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα.

  2019cites this paper
• Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential

  2019cites this paper
• Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance

  2019cites this paper
• The Diverse Roles of RNA-Binding Proteins in Glioma Development.

  2019cites this paper
• An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types

  2019cites this paper
• Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas

  2019cites this paper
• GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients

  2019cites this paper
• In Ganoderma lucidum, Glsnf1 regulates cellulose degradation by inhibiting GlCreA during the utilization of cellulose.

  2019cites this paper
• Glioma Stem Cell Specific Super Enhancer Promotes Polyunsaturated Fatty Acid Synthesis to Support EGFR Signaling.

  2019cites this paper
• AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2

  2018cites this paper
• SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy.

  2018cites this paper
• Multiple chemo-genetic interactions between a toxic metabolite and the ubiquitin pathway in yeast

  2018cites this paper
• Lipid metabolism reprogramming and its potential targets in cancer

  2018cites this paper
• EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition

  2018cites this paper
• AMP Kinase Promotes Glioblastoma Bioenergetics and Tumor Growth

  2018cites this paper
• Metabolomics and proteomics identify the toxic form and the associated cellular binding targets of the anti-proliferative drug AICAR

  2018influential citation
• WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.

  2018cites this paper
• A new drug combination significantly reduces kidney tumor progression in kidney mouse model

  2018cites this paper
• Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation

  2018cites this paper
• mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression

  2018cites this paper
• Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2

  2018cites this paper
• Preclinical evidence of the enhanced effectiveness of combined rapamycin and AICAR in reducing kidney cancer

  2018cites this paper
• Targeting epidermal growth factor receptor co‐dependent signaling pathways in glioblastoma

  2018cites this paper
• Identification of Grade-associated MicroRNAs in Brainstem Gliomas Based on Microarray Data

  2018cites this paper
• Nucleosides block AICAR-stimulated activation of AMPK in skeletal muscle and cancer cells.

  2018cites this paper
• Purine synthesis promotes maintenance of brain tumor initiating cells in glioma

  2017cites this paper
• Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells

  2017cites this paper
• EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells.

  2017cites this paper
• Metabolic Reprogramming in Brain Tumors.

  2017cites this paper
• Targeting autophagy in cancer

  2017cites this paper
• Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?

  2017cites this paper
• Lipid droplets, potential biomarker and metabolic target in glioblastoma.

  2017cites this paper
• Treatment with AICAR inhibits blastocyst development, trophectoderm differentiation and tight junction formation and function in mice

  2017cites this paper
• Antiglioma effects of N6‐isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor

  2017cites this paper
• microRNA-29 mediates a novel negative feedback loop to regulate SCAP/SREBP-1 and lipid metabolism.

  2017cites this paper
• 3 Key Principles in Glioblastoma Therapy

  2017cites this paper
• Ginsenoside Rb3 strengthens the hypoglycemic effect through AMPK for inhibition of hepatic gluconeogenesis.

  2017cites this paper
• SCAP links glucose to lipid metabolism in cancer cells

  2016cites this paper
• Analysis of SCAP N-glycosylation and Trafficking in Human Cells.

  2016cites this paper
• AMPK Regulation of Cell Growth, Apoptosis, Autophagy, and Bioenergetics.

  2016cites this paper